skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Tucidinostat (Code C97263)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Tucidinostat

Definition: An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Upon administration, tucidinostat binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.

Display Name: Tucidinostat

Label: Tucidinostat

NCI Thesaurus Code: C97263 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2932486  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
N-(2-amino-5-fluorine benzyl)-4-[N-(pyridine-3-acrylyl) ammonia methyl] Benzamide

External Source Codes: 
CAS Registry Number 1616493-44-7 (see NLM ChemIDplus info)
FDA UNII Code 87CIC980Y0
PDQ Closed Trial Search ID 702501
PDQ Open Trial Search ID 702501 (check for NCI PDQ open clinical trial info)
UMLS CUI C2932486

Other Properties:
     Name Value (qualifiers indented underneath)
code C97263
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom